Lung Cancer News & Features
New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
[OncoTargets and Therapy] Evidence increasingly suggests that pembrolizumab has a significant role in first- and second-line therapy for NSCLC. This review presents the results of previous and ongoing studies and discusses biomarkers that can potentially identify eligible candidates for treatment with the PD-L1 inhibitor.
Mortality Rates for Lung Cancer Likely to Surpass Breast Cancer Among Women by 2030
Screening practices and smoking habits are expected to have a significant impact on mortality rates for lung cancer and breast cancer among women in high-income countries.
Link Between Asbestos-Free Talcum Powder and Cancer Unclear
Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.
Lung Cancer Screening: Effective Models for Selecting the Most Candidates at Highest Risk
Four of 9 lung cancer screening models were shown to effectively select the most appropriate candidates for low-dose CT lung cancer screening among US ever-smokers.
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Drug Treatments
Non-small cell lung cancer (NSCLC) treatment regimen chart.0
Lung Cancer: What Nurse Navigators Need to Know in 2018
There have been many recent changes in lung cancer, including updated early detection possibilities and changes in diagnostic procedures, reporting, and treatment options. These are reviewed in a presentation at the 2018 ONA Navigation Summit.
Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy
A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.
Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Response to Rapamycin Analogs but not PD-1 Inhibitors in PTEN-mutated Metastatic Non-small Cell Lung Cancer With High Tumor Mutational Burden
[Lung Cancer: Targets and Therapy] This case study demonstrates that genomic profiling may still benefit patients who fail checkpoint inhibitor therapy despite having high tumor mutational burden and PD-L1 positivity.
Lung Cancer Incidence is Higher for Young Women Than Young Men
Researchers observed a decrease in the age-specific incidence of lung cancer among both men and women aged 30 to 54 years over the past two decades; the declines among men were steeper.
Lung Cancer Clinical Trials
Sign Up for Free e-newsletters
ONA Articles
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- Combined Digital Screening Best for Detecting Breast Cancers
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Seeking Reliable Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- The Efficacy and Tolerance of High Pressure Oxygen Combined With Chemotherapy in Postoperative Patients With Advanced Gastric Cancer
- Hepatocellular Cancer Pain: Impact and Management Challenges
- Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia
- Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT
- Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |